BeOne Medicines clinical trial pipeline

12 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 9 with minor changes only.

1. Notable

   Treatment · B-Cell Malignancies With BGB-16673, a Bruton…Treatment · B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

   Sponsor changed: BeiGene to BeOne Medicines

   Also in this update: Primary endpoint(s) modified; Primary completion moved earlier from Jan 31, 2029 to Jun 30, 2027

   BeOne Medicines·Phase 1/2· NCT05294731· Registry history of NCT05294731 on ClinicalTrials.gov (opens the registry)

   Oct 21, 2026

2. Notable

   Investigational Study of BGB-58067 As a Single Agent and in…Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents · Advanced Solid Tumors

   Primary and study completion pushed from Sep 30, 2027 to Aug 31, 2028

   Also in this update: Primary endpoint(s) modified; Enrollment increased: 525 → 695 participants

   BeOne Medicines·Phase 1· NCT06589596· Registry history of NCT06589596 on ClinicalTrials.gov (opens the registry)

   Oct 20, 2026

3. Notable

   Healthy Participants to Assess Drug Interaction Potential of…Healthy Participants to Assess Drug Interaction Potential of BGB-43395

   Recruitment opened

   Also in this update: Start date changed from estimate of Sep 24, 2026 to Sep 25, 2026

   BeOne Medicines·Phase 1· NCT07820891· Registry history of NCT07820891 on ClinicalTrials.gov (opens the registry)

   Oct 8, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.